Exelixis (EXEL) vs Moderna (MRNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Moderna (MRNA) has outperformed Exelixis (EXEL) over the past year, gaining 605.6% versus a gain of 52.7%. Over five years, EXEL leads with a +170.5% price change compared with -39.4% for MRNA. Moderna is the larger company by market cap ($78.65 billion vs $14.62 billion), about 5.4 times the size, while Exelixis is growing revenue faster (+7.0% vs -39.9%).
Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | MRNA |
|---|---|---|
| Share price | $59.02 | $197.00 |
| Market cap | $14.62B | $78.65B |
| 1-day change | +0.99% | +0.26% |
| YTD return | +34.66% | +568.02% |
| 1-year return | +52.74% | +605.59% |
| 5-year return | +170.49% | -39.40% |
| P/E ratio (TTM) | 18.62 | — |
| Forward P/E | 13.92 | — |
| EPS (TTM) | $3.17 | $-7.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $1.94B |
| Revenue growth (YoY) | +6.98% | -39.93% |
| Net income (latest FY) | $782.57M | $-2.82B |
| Gross margin | 96.39% | 55.35% |
| Operating margin | 37.59% | -158.13% |
| Net margin | 33.73% | -145.16% |
| 52-week high | $61.14 | $212.22 |
| 52-week low | $33.76 | $22.28 |
| Distance from 52-week high | -3.47% | -7.17% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -7.61% | -38.58% |
| Average volume | 2.34M | 17.44M |
| Shares outstanding | 247.78M | 399.24M |
| Employees | 1,077 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 5.4 times larger than Exelixis by market value ($78.65B vs $14.62B).
- MRNA has outperformed EXEL by 552.8 percentage points over the past year.
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Exelixis grew revenue faster in its latest fiscal year (+6.98% vs -39.93%).
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
EXEL vs MRNA FAQ
Which is bigger, Exelixis or Moderna?
Moderna (MRNA) is larger, with a market capitalization of $78.65B compared with $14.62B for Exelixis (EXEL).
Which stock has performed better over the past year, EXEL or MRNA?
MRNA returned +605.59% over the past 12 months, compared with +52.74% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Moderna in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.